Status:
COMPLETED
Effect of Urine Alkalinazation on Urinary Inflammatory Markers in Patients With Cystinuria
Lead Sponsor:
European Georges Pompidou Hospital
Collaborating Sponsors:
Institut National de la Santé Et de la Recherche Médicale, France
Sponsor Name Pending
Conditions:
Cystinuria
Renal Lithiasis
Eligibility:
All Genders
18+ years
Brief Summary
It has recently been described the presence of a urinary inflammatory signature in patients with cystinuria, the most common cause of renal lithiasis of genetical origin. These data are very innovativ...
Eligibility Criteria
Inclusion
- age superior or equal to 18 years
- patient able to understand the information note and to sign the informed consent
- patient with an Health coverage
- no current urinary tract infection (assessed by a cytobacteriological examination of the urine)
- For the cystinuria group: patient with cystinuria not yet treated or for whom the alkalizing treatment or the cystein binding thiol agents have been discontinuated for at least 3 months AND with an estimated GFR (using the MDRD formula) greater than 60 ml/min/1.73m2.
- For the control groups: patient presenting either a renal lithiasis not due to cystinuria, or an inflammatory renal pathology confirmed by an anterior renal biopsy (glomerulonephritis or interstitial nephritis) AND with an estimated GFR (using the MDRD formula) greater than 30 ml/ min/1.73m2.
Exclusion
- Cystinuric patient already treated (whatever the treatment)
Key Trial Info
Start Date :
April 2 2015
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2020
Estimated Enrollment :
63 Patients enrolled
Trial Details
Trial ID
NCT03836144
Start Date
April 2 2015
End Date
December 31 2020
Last Update
March 22 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Eurpean Georges Pompidou Hospital
Paris, Île-de-France Region, France, 75015